Sling Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2020-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://slingtx.com
Clinical Trials
5
Active:3
Completed:0
Trial Phases
2 Phases
Phase 1:3
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (60.0%)Phase 2
2 (40.0%)Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Phase 2
Recruiting
- Conditions
- ExophthalmosEye DiseasesProptosisThyroid Eye DiseaseGraves OrbitopathyThyroid Associated OphthalmopathyGraves OphthalmopathyOrbital DiseasesEndocrine System DiseasesThyroid Diseases
- Interventions
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Sling Therapeutics, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT06112340
- Locations
- 🇺🇸
Bascom Palmer Eye Institute, Miami, Florida, United States
🇺🇸West Virginia University Eye Institute, Morgantown, West Virginia, United States
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Phase 2
Active, not recruiting
- Conditions
- Thyroid Eye DiseaseOrbital DiseasesExophthalmosThyroid Associated OphthalmopathyGraves OrbitopathyEndocrine System DiseasesThyroid DiseasesIGF1REye DiseasesGraves Ophthalmopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Sling Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05276063
- Locations
- 🇺🇸
Thrive Health Research, Beverly Hills, California, United States
🇺🇸UC San Diego Health, La Jolla, California, United States
🇺🇸UCLA, Los Angeles, California, United States
News
No news found